ZMapp, 'modern techniques' too late to save doctor

The death of a doctor who was being treated for Ebola in the US with the best of what medical care has to offer, including the hard-to-obtain experimental drug ZMapp, was a stark reminder that in the very advanced stages, even the most modern techniques are not enough to save a patient's life when they reach a critical threshold, said Dr Jeff Gold, chancellor of the University of Nebraska Medical Center (UNMC) in Omaha.

The death of a doctor who was being treated for Ebola in the US with the best of what medical care has to offer, including the hard-to-obtain experimental drug ZMapp, was a stark reminder that in the very advanced stages, even the most modern techniques are not enough to save a patient's life when they reach a critical threshold, said Dr Jeff Gold, chancellor of the University of Nebraska Medical Center (UNMC) in Omaha.

Dr Martin Salia, a US national who was serving in his native Sierra Leone as a surgeon when he contracted Ebola, was not flown to the US for treatment until...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immunological

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By 

Buy boosts the French major's immunology pipeline.

More from Therapy Areas

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By 

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.